Beam Therapeutics (BEAM) Corporate presentation summary

Vision and technology

• Aims to provide lifelong, one-time curative therapies for rare and common diseases using base editing technology, offering predictable and durable gene correction with less genotoxicity than traditional methods.

• Platform enables rapidly programmable precision medicines adaptable to new targets, with reusable delivery technology and scalable internal manufacturing.

Financial strength and growth

• Holds $1.2 billion in cash as of June 30, 2026, plus potential $200 million from a credit facility, expected to fund operations into mid-2029.

• Focused investment strategy supports efficient commercial build and pipeline expansion, targeting significant addressable markets.

Liver-targeted genetic disease franchise

• Advancing a portfolio of in vivo programs for diseases like AATD, GSDIa, and PKU, leveraging industry-leading LNP capabilities.

• BEAM-302 for AATD shows durable AAT increases above protective thresholds, with 84% reduction in mutant Z-AAT and favorable safety profile; pivotal trial dosing initiated in July 2026.

• BEAM-304 for PKU and BEAM-301 for GSDIa designed for early clinical proof of concept, with preclinical data supporting rapid normalization of disease markers.